Efficacy of the latanoprost versus timolol/dorzolamide combination therapy in patients with primary open angle glaucoma

Saudi Medical Journal

Volumn 29, Issue 3, 2008, Pages 384-387

  Rismanchian, Akram ^a   Eslami, Fateme ^a   Moeini, Heidarali ^a   Attarzade, Hosein ^a   Naderibeni, Afsane ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; ANTIHYPERTENSIVE AGENT; DORZOLAMIDE; PROSTAGLANDIN F; SULFONAMIDE; THIOPHENE DERIVATIVE; TIMOLOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; IRAN; MAJOR CLINICAL STUDY; MALE; OCULOPLETHYSMOGRAPHY; OPEN ANGLE GLAUCOMA; OPHTHALMOSCOPY; OUTCOME ASSESSMENT; PRESSURE MEASUREMENT; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SLIT LAMP; TREATMENT DURATION; COMPARATIVE STUDY; DRUG COMBINATION; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; MALE; MIDDLE AGED; PROSTAGLANDINS F, SYNTHETIC; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 47549097405     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR, Adamsons IA; COSOPT versus XALATAN Study Groups. Efficacy and tolerability of dorzolamide 2%/ timolol 0.5% combination (COSOPTTM) versus latanoprost 0.005% (XALATANTM) in the treatment of ocular hypertension or glaucoma: Results from two randomized clinical trials. Acta Ophthalmol Scand 2004; 82: 42-48.
2. Emmerich KH. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension. A 3-month randomised study. Graefes Arch Clin Exp Ophthalmol 2000; 238: 19-23.
3. Uusitalo RJ, Palkama A. Long-term evaluation of timolol. Acta Ophthalmol 1989: 67: 573-581.
4. Toris CB, Camras CB, Yablonski ME, Effects of PhXA41, a new prostaglandin F2a analog, on aqueoushumor dynamics in human eyes. Ophthalmology 1993; 100: 1297-1304.
5. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2a analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993; 111: 1351-1358.
6. Larsson LI, Mishima HK, Takamatsu M. The effect of latanoprost on circadian intraocular pressure. Surv Ophthalmol 2000; 47(Suppl 1): S90-S96.
7. Susanna R Jr, Sheu WP; Latin American Glaucoma Society. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure:aNd eight-week, randomized, open-label, parallel-group, multicenter study in Latin America. Clin Ther 2004; 26: 755-768.
8. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology 1996; 103: 1916-1924.
9. Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology 1998; 105: 82-87.
10. Fechtner RD, McCarroll KA, Lines CR, Adamsons IA. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: Combined analysis of pooled data from two large randomzed observer and patient-masked studies. J Ocul Pharmacol Ther 2005; 21: 242-249.
11. Liesegang TJ, Skuta GL, Cantor LB, Medical management of glaucoma. Basic and clinical science course, lens and cataract section 11. San Francisco, USA: American academy of opthalmology; 2004. p. 173-175.
12. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9: 134-142.
13. Bergeå B, Bodin L, Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology 1999; 106: 997-1004.
14. Honrubia FM, Larsson LI, Spiegel D; European latanoprost study group. A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma. Acta Ophthalmol Scand 2002; 80: 635-641.
15. Grierson I, Cracknell KP, Pfeiffer N. The iris after prostanoid treatment. Curr Opin Ophthalmol 2001; 12: 112-118.
16. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997; 124: 544-547.
17. Konstas AG, Papapanos P, Tersis I, Houliara D, Stewart WC. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology 2003; 110: 1357-1360.